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Background
The next generation NNRTI etravirine (ETR, TMC125) and
the fusion inhibitor enfuvirtide (T-20) have shown strong
efficacy in the DUET and TORO trials, respectively.
Switching from enfuvirtide to etravirine could improve
convenience and tolerability, and reduce treatment costs.
In the TMC125-C214 trial (global etravirine expanded
access programme), treatment-experienced patients with
undetectable HIV-RNA levels were permitted to switch
from enfuvirtide to etravirine.
Methods
Patients who switched from enfuvirtide to etravirine, with
screening HIV-RNA less than 50 copies/mL, were followed
up for 24 weeks. Data were monitored and analysed for
patients in Europe and Canada. Patients could optimise
other parts of the background regimen at the time of
switch from enfuvirtide to etravirine.
Summary of results
Overall, there were 34 patients switching from enfuvirtide
to etravirine in Europe (n = 24) and Canada (n = 10). Of
these, 24% were female, 97% were Caucasian, with a
mean age of 48 years. The baseline median CD4 count
was 351 cells/uL (range 90–935). Within this study, 33 of
the 34 patients (97%) used DRV/r in the background reg-
imen, with raltegravir used in 50%, maraviroc in 9%, and
NRTIs for 91%. The percentage of patients with HIV-RNA
suppressed below 50 copies/mL was 83% at week 4, 86%
at week 12 and 93% at week 24. Of those with HIV-RNA
not <50 copies/mL at week 12, there were five HIV-RNA
levels just above the detection limit (50, 52, 52, 58 and
217 copies/mL) and one patient with HIV-RNA = 5,070.
This patient also had HIV-RNA above 50 copies/mL at
week 24 (4,730 copies/mL). Mean CD4 counts remained
above baseline through week 24. There were four serious
adverse events reported: these were all judged to be unre-
lated to etravirine treatment by the investigators and the
dose of etravirine was not changed.
Conclusion
The vast majority of patients who switched from enfuvir-
tide to etravirine have sustained HIV-RNA suppression
below 50 copies/mL for up to 24 weeks of study, with sta-
ble or rising CD4 counts.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P37 doi:10.1186/1758-2652-11-S1-P37
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P37
© 2008 Ribera et al; licensee BioMed Central Ltd. 
